The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
Reason given: Logistics and low enrollment.
Key facts
- Where
- Valhalla, United StatesSee the site
Where in United States
- Westchester Medical CenterValhalla, United StatesNo longer taking part
Trial details
- Who runs it
- Nanowear Inc.
- Trial code
- NCT05629533
- Record updated
- 9 April 2026
- Original description
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases. Phase 1 will use SimpleSense data collected from the first set of subjects and associate the data from SimpleSense to the right heart catheterization values.' Phase 2 will evaluate the algorithms developed to estimate cardiac output from SimpleSense data using a second set of subjects from within the sample population that are sequestered from the first set used for association of data from SimpleSense to the data from the right heart catheterization.Read full original descriptionShow less
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output, Cardiac Power Output and Pulmonary Artery Pressure.in Patients Undergoing Right Heart Catheterization
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases. Phase 1 will use SimpleSense data collected from the first set of subjects and associate the data from SimpleSense to the right heart catheterization values.' Phase 2 will evaluate the algorithms developed to estimate cardiac output from SimpleSense data using a second set of subjects from within the sample population that are sequestered from the first set used for association of data from SimpleSense to the data from the right heart catheterization.
Inclusion: Subject has provided informed consent; Male or female over the age of 18 years; The patient is undergoing right heart catheterization.
Exclusion: Subject unwilling or unable to comply with wearing the Nanowear SimpleSense System; Subjects who are pregnant; Severe aortic stenosis.